Anticoagulant therapy in COVID-19 critically ill: Should we go for more?

被引：0

作者：

Vandenbriele, C. ^{[1
]}

Van Aelst, L. ^{[1
]}

Balthazar, T. ^{[1
]}

Dauwe, D. ^{[2
]}

Delcroix, M. ^{[3
]}

Gunst, J. ^{[2
]}

Huber, K. ^{[4
,5
]}

Jacquemin, M. ^{[1
]}

Peerlinck, K. ^{[1
]}

Vanassche, T. ^{[1
]}

Wauters, J. ^{[6
]}

Wilmer, A. ^{[6
]}

Verhamme, R. ^{[1
]}

机构：

[1] Univ Hosp Leuven, Dept Cardiovasc Dis, Leuven, Belgium

[2] Univ Hosp Leuven, Dept Intens Care Med, Leuven, Belgium

[3] Univ Hosp Leuven, Dept Pneumol, Leuven, Belgium

[4] Wilhelminenhosp, Dept Med Cardiol & Intens Care Med 3, Vienna, Austria

[5] Sigmund Freud Univ, Med Fac, Vienna, Austria

[6] Univ Hosp Leuven, Dept Internal Med, Leuven, Belgium

来源：

JOURNAL FUR KARDIOLOGIE | 2020年 / 27卷 / 05期

关键词：

COVID-19; infection; pro-thrombotic milieu; deep vein thrombosis; pulmonary embolism; myocardial infarction; antithrombotic; strategy;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Critically ill COVID-19 patients often develop a severe pro-thrombotic milieu, as reflected by the markedly increased d-dimer -levels. Several cohort studies have reported high rates of thrombotic complications, including deep venous thrombosis (DVT) and pulmonary embolism (PE), myocardial infarction, stroke and microvascular thrombosis. Accordingly, COVID-19 patients who are hospitalized either at a normal, non-intensive care unit (ICU) or at the ICU need to receive appropriate dosages of anticoagulant therapy to prevent or treat these thrombotic complications. This manuscript summarizes the institutional guidance for the antithrombotic prophylaxis and treatment of VTE as outlined by a multidisciplinary team of experts during the first weeks of the COVID-19 pandemic in Europe. Controlled studies are needed to verify the optimal anti-coagulation for both prophylaxis and treatment.

引用

页码：156 / 158

页数：3

共 21 条

[1]

[Anonymous], 2020, INCIDENCE VENOUS THR, DOI DOI 10.20944/PREPRINTS202004.0345.V1

[2]

[Anonymous], 2020, PROPOSITIONS GIHP GF

[3]

[Anonymous], COVID 19 ASS INCREAS

[4]

[Anonymous], LANCET INFECT DIS

[5]

[Anonymous], 2020, J THROMB HAEMOST

[6]

[Anonymous], J THROMB HAEMOST

[7]

[Anonymous], 2020, GASTROENTEROLOGY

[8] COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow [J].

Bikdeli, Behnood ;

Madhavan, Mahesh V. ;

Jimenez, David ;

Chuich, Taylor ;

Dreyfus, Isaac ;

Driggin, Elissa ;

Der Nigoghossian, Caroline ;

Ageno, Walter ;

Madjid, Mohammad ;

Guo, Yutao ;

Tang, Liang V. ;

Hu, Yu ;

Giri, Jay ;

Cushman, Mary ;

Quere, Isabelle ;

Dimakakos, Evangelos P. ;

Gibson, C. Michael ;

Lippi, Giuseppe ;

Favaloro, Emmanuel J. ;

Fareed, Jawed ;

Caprini, Joseph A. ;

Tafur, Alfonso J. ;

Burton, John R. ;

Francese, Dominic P. ;

Wang, Elizabeth Y. ;

Falanga, Anna ;

McLintock, Claire ;

Hunt, Beverley J. ;

Spyropoulos, Alex C. ;

Barnes, Geoffrey D. ;

Eikelboom, John W. ;

Weinberg, Ido ;

Schulman, Sam ;

Carrier, Marc ;

Piazza, Gregory ;

Beckman, Joshua A. ;

Steg, Gabriel ;

Stone, Gregg W. ;

Rosenkranz, Stephan ;

Goldhaber, Samuel Z. ;

Parikh, Sahil A. ;

Monreal, Manuel ;

Krumholz, Harlan M. ;

Konstantinides, Stavros V. ;

Weitz, Jeffrey I. ;

Lip, Gregory Y. H. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (23) :2950-2973

[9] Blood coagulation in immunothrombosis-At the frontline of intravascular immunity [J].

Gaertner, Florian ;

Massberg, Steffen .

SEMINARS IN IMMUNOLOGY, 2016, 28 (06) :561-569

[10] COVID-19 pneumonia: different respiratory treatments for different phenotypes? [J].

Gattinoni, Luciano ;

Chiumello, Davide ;

Caironi, Pietro ;

Busana, Mattia ;

Romitti, Federica ;

Brazzi, Luca ;

Camporota, Luigi .

INTENSIVE CARE MEDICINE, 2020, 46 (06) :1099-1102

← 1 2 3 →